Percheron Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Percheron Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Percheron Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Percheron Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Percheron Therapeutics Ltd (Percheron), formerly Antisense Therapeutics Ltd, is a clinical-stage drug development company focused on advancing therapies in the field of immuno-oncology. The company focuses on the development and commercialization of drug candidates targeting challenging diseases. Percheron's major product is HMBD-002, a recombinant humanized monoclonal antibody targeting the VISTA protein, which is under investigation for its potential applications in treating various solid tumors and hematological malignancies. The company’s second candidate, ATL1103, targets the growth hormone receptor for acromegaly treatment. The company's products are intended for use by healthcare providers and researchers in the medical and pharmaceutical industries. Percheron collaborates with partners such as Hummingbird Bioscience to enhance its drug development efforts. Percheron is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
L30, Collins Place, 35 Collins Street, Melbourne, Victoria, 3000
Website
www.percherontx.com
Telephone
61 3 98278999
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PER (ASX)
Revenue (2024)
$94,900
-39.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-25.2%
(2024 vs 2023)
Market Cap*
$5.9M
Net Profit Margin (2024)
XYZ
-107.6%
(2024 vs 2023)
* As of and is in US$
Percheron Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| HMBD-002: Monoclonal Antibody |
| Atesidorsen (ATL1103): Acromegaly |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In January, the company changed its name to Percheron Therapeutics Ltd. |
| 2023 | Regulatory Approval | In June, the company secured regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the UK. |
| 2023 | Regulatory Approval | In February, the company secured regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne Muscular Dystrophy. |
Competitor Comparison
| Key Parameters | Percheron Therapeutics Ltd | Sarepta Therapeutics Inc | Clinuvel Pharmaceuticals Ltd | Wave Life Sciences Ltd | Genetic Technologies Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Australia | Singapore | Australia |
| City | Melbourne | Cambridge | Melbourne | Singapore City | Melbourne |
| State/Province | Victoria | Massachusetts | Victoria | - | Victoria |
| No. of Employees | 8 | 835 | 100 | 317 | 58 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Garner | Chief Executive Officer; Managing Director | Senior Management | 2023 | - |
| Deborah Ambrosini | Secretary; Chief Financial Officer | Senior Management | 2024 | - |
| Valentina Dubljevic | Chief Technology Officer | Senior Management | 2025 | - |
| Eugene Kennedy | Chief Medical Officer | Senior Management | 2025 | - |
| Charmaine Gittleson, M.D. | Chairperson | Non Executive Board | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer